10X Genomics, Inc. (TXG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$62.65-0.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
10x Genomics aims to grow revenue to about $612.5M in 2026. It targets positive cash flow from operations, with $26.1M achieved in Q1. The company focuses on improving gross profit, which was $106.2M in Q1. Recent earnings beats show progress despite losses.
Revenue growth may stall below guidance of $600M-$625M. Cash flow could weaken from $26.1M in Q1. Profit margins might not improve, risking sustained losses. Insider selling raises concerns about management confidence.
The price is about 34% above our fair value near $28. Analysts expect modest 3% revenue growth. Our fair value is slightly below the Street median of $30, reflecting skepticism on growth and profitability.
Breaks if: gross profit falls below $100M in any quarter
Breaks if: CEO or CFO sells large share blocks repeatedly
Breaks if: operating cash flow turns negative for two consecutive quarters
Focus on improving cash flow from operations to positive levels as part of financial discipline and operational efficiency.
Stated as a priority in 3 of last 3 quarters. Cash from operating activities declined from $40.78M in 2025-Q4 to $16.97M in 2026-Q2, indicating limited progress toward improving cash flow despite management focus. The trajectory is mixed with recent quarters showing declining cash flow.
“Cash from operating activities was $16.97 million in 2026-Q2”
“Cash from operating activities was $26.12 million in 2026-Q1”
“Cash from operating activities was $40.78 million in 2025-Q4”
Breaks if: revenue falls below $600M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity with some speculative elements. The current thesis state is intact, backed by recent earnings beats and management's focus on revenue growth.
The market appears to price in a level of fragility due to TXG's expensive valuation compared to peers. There is an expectations gap indicating that the market may not fully recognize the potential for future growth despite recent performance.
Management is on track with revenue guidance and improving gross margins, but cash flow from operations shows mixed results. Near-term risks include the potential for earnings misses, although the probability is relatively low.
The thesis hinges on maintaining revenue guidance and positive cash flow, as well as the performance of sector bellwethers. Additionally, any reversal in guidance could significantly impact credibility and market perception.
Overall, TXG's performance and management execution will be crucial over the next few years. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a better outlook. The company maintained and raised its 2026 revenue guidance. Strong early orders for the Atera platform also boost expectations. RBC Capital initiated coverage with a Sector Perform rating and a $70 estimate.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.